695
Participants
Start Date
June 24, 2022
Primary Completion Date
June 1, 2027
Study Completion Date
June 1, 2027
AZD9574
Participants will receive AZD9574 orally.
Temozolomide (TMZ)
Participants will receive temozolomide orally.
[11C]AZ1419 3391
Participants will receive \[11C\]AZ1419 3391 intravenously.
Trastuzumab Deruxtecan (T-DXd)
Participants will receive T-DXd intravenously.
Datopotamab Deruxtecan (Dato-DXd)
Participants will receive Dato-DXd intravenously.
RECRUITING
Research Site, Darlinghurst
RECRUITING
Research Site, Randwick
RECRUITING
Research Site, Camperdown
RECRUITING
Research Site, Melbourne
RECRUITING
Research Site, Barcelona
RECRUITING
Research Site, New York
RECRUITING
Research Site, New York
WITHDRAWN
Research Site, Berlin
RECRUITING
Research Site, A Coruña
ACTIVE_NOT_RECRUITING
Research Site, Lund
WITHDRAWN
Research Site, Richmond
RECRUITING
Research Site, Pozuelo de Alarcón
NOT_YET_RECRUITING
Research Site, Málaga
RECRUITING
Research Site, Seville
WITHDRAWN
Research Site, Mainz
RECRUITING
Research Site, Chicago
WITHDRAWN
Research Site, Heidelberg
RECRUITING
Research Site, Houston
NOT_YET_RECRUITING
Research Site, San Antonio
WITHDRAWN
Research Site, Bayern
RECRUITING
Research Site, Los Angeles
WITHDRAWN
Research Site, La Jolla
RECRUITING
Research Site, San Francisco
ACTIVE_NOT_RECRUITING
Research Site, Portland
RECRUITING
Research Site, Boston
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Sant Cugat del Vallès
RECRUITING
Research Site, Stockholm
RECRUITING
Research Site, Glasgow, Scotland
RECRUITING
Research Site, London
RECRUITING
Research Site, Newcastle upon Tyne
Lead Sponsor
AstraZeneca
INDUSTRY